Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 218, Issue -, Pages S588-S591Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy332
Keywords
antiviral; bepridil; Marburg virus
Categories
Funding
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID)
- Integrated Research Facility (NIAID, Division of Clinical Research)
- Battelle Memorial Institute
- NIAID [HHSN272200700016I]
Ask authors/readers for more resources
No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridil's broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available